Background: Carbapenem-resistant Enterobacteriaceae (CRE) are multidrug-resistant microorganisms. Infections caused by these microorganisms have limited treatment options, frequently leading to high mortality rates.
Introduction
Among the gram-negative bacteria is the large family Enterobacteriaceae, which is normally found in the gastrointestinal tracts of humans and animals. They are considered the common pathogens that cause several severe infections, including bloodstream infections, community-acquired pneumonia and hospital-acquired pneumonia (1). Carbapenem is a β-lactam antibiotic, which inhibits transpeptidases (penicillin-binding proteins) and prevents peptidoglycan synthesis, leading to lytic cell death. Carbapenems represent an important class of antimicrobials that have been used for the treatment of such infections (2) . However, several studies have reported the emergence of carbapenem-resistant Enterobacteriaceae (CRE), which have a β-lactamase, carbapenemase, facilitating the hydrolysis of a broad variety of β-lactams. CRE are multidrug-resistant microorganisms; thus, infections caused by these microorganisms have limited treatment options, leading to a high mortality rate. The resistance of CRE to carbapenems is generally based on two mechanisms: carbapenemase production or the combination of structural mutations with the production of other β-lactamases, such as AmpC cephalosporinase and Extended-spectrum Betalactamases (ESBL) (3, 4) . The mortality rate in CRE-infected patients typically ranges from 18% to 48%, depending on the treatment regimen. The high mortality rate may be attributed to a delay in therapy, limited availability of treatment options, or the fact that infected patients are usually critically ill (5, 6) . In Saudi Arabia, nine of 29 patients (31%) with CRE infection died compared with 7/58 (12.1%) of their matched controls. The mortality was associated with old age, comorbidities, previous use of carbapenem, ICU admission, mechanical ventilation and central line insertion (6) . Healthcare settings are considered high-risk environments for acquisition of CRE infection, which can occur through direct contact with infected patients, contaminated surfaces, or healthcare personnel. In addition, several medical procedures and devices have been reported to contribute to CRE infections, such as recent organ or stem-cell transplantation, receipt of mechanical ventilation as well as prolonged hospital stay (7) . Among the most frequent source of CRE infections reported by De Oliveira et al. was the catheter-related bloodstream infection, which resulted in an overall 30-day mortality rate of 45% (8) .
Infection with CRE is considered serious and difficult to be treated because it is accompanied with significant morbidity and mortality (4, 9) . The available studies that provide evidence to support the clinical use of the antimicrobial agents currently used for treatment of CRE-caused infections are scarce. These drugs included carbapenem combinations, polymyxins, fosfomycin, tigecycline, aminoglycosides, ceftazidime-avibactam, and meropenem-vaborbactam. Unfortunately, the use of many of these drugs is limited because of their toxicities and pharmacokinetics properties (10) . New treatments with activity against CRE like new beta-lactamase combinations are currently being studied to help diminish the resistance against these drugs, and early results suggest they are safer and more efficacious compared with some older drugs (11) . The greater understanding of the risk factors associated with CRE infections is critical for the effective treatment of CRE-infected patients. In the present study, the clinical and microbiological characteristics of CRE infections, treatment regimens, infection-related mortality, and risk factors associated with the death of infected patients were analyzed.
Material and Methods

Study Design and Setting
All medical records of patients (n=118) with CRE infections at King Abdulaziz University Hospital from January 1, 2014 to December 31, 2016 were retrospectively analyzed. The data of all patients with CRE infections at a sterile site during the study period were included. These patients had positive cultures for a CRE isolate from infected sites. The records of patients without CRE infections or patients that were only colonized rather than infected with CRE were excluded.
Data Collection and Analysis
Medical records were reviewed to analyze patient demographics, CRE risk factors, site of infection, antibiotic treatment, presence of septic shock (septic shock at the time of culture), comorbidities, colistin use, and admission to the intensive care unit (ICU) or the ward. In addition, patients were categorized based on the number of comorbidities (1, 2, or ≥3), the therapeutic regimen included monotherapy or combination therapy (2, 3, or 4 drugs) and treatment duration (<12 h, 12-24 h, or >24 h). The clinical outcome in this study was 30-day mortality (death within 30 days after the first positive culture). For CRE Identification, carbapenem susceptibility testing was initiated first using antimicrobial susceptibility panels for the VITEK® 2 system. If the results revealed resistance according to the minimum inhibitory concentration (MIC) of Clinical & Laboratory Standards Institute CLSI then confirmation by E test was performed. If resistance was confirmed a GeneXpert PCR was done to detect whether the gene of resistance was VIM, IMP, OXa 48, NDM or KPC genes.
Statistical Analysis
All statistical analyses were conducted using IBM© SPSS© Statistics version 21 (IBM© Corp., Armonk, NY, USA). Descriptive statistics were used to describe the patients' characteristics. Continuous variables were compared using independent-samples t-test and were expressed as mean ± standard deviation (SD). The categorical variables were compared using the Chi-Square test of independence and Fisher's exact test. The primary outcome was 30-day mortality. Survival curves were constructed for monotherapy and combination therapies, and differences were analyzed using a log-rank test. Results are expressed as Odds ratio and 95% confidence interval (CI). All tests were two-tailed, and a p value of <0.05 was considered to be statistically significant.
Ethics of research
This study was approved by the Biomedical ethics research committee at the Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia (Ref: [9] [10] [11] [12] [13] [14] [15] [16] [17] . The private and sensitive information in the records of the patients are kept confidential. Declaration of Helsinki -ethical principles for medical research involving human subjects (adopted by the 18th General Assembly of World Medical Association [WMA], Helsinki, Finland, June 1964 and last amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013) was considered throughout the designing of the study protocol and its implementation.
Results
The demographics and clinical characteristics of CRE patients are summarized in Table 1 . The mean age of the patients in this study was 58.05 (±19.4). During the study period, 118 patients developed infections caused by CRE; 81 of them were admitted to the ICU (68.6%). The mean age of patients who survived with CRE infections was 61.9 (±17.38) years, whereas that of the deaths was 55.5 (±20.38) years. In addition, 54 (45.8%) patients were male (the survivors were 37 (51.4%) while deaths were 17 (37.0%)). pneumoniae and E. coli (n=1, 0.8%), and Klebsiella oxytoca (n=1, 0.8%). Among patients who were positive for CRE infections, 59 (50%) had previously undergone surgery, while 83 (70.3%) had renal dysfunction. The common sources of CRE infection were the chest (n=26, 22%), the urinary tract (n=26, 22%), abdominal (n=22, 18.6%), and multiple sites (n=31, 26.3%). Comorbidities were present in 97.5% of cases (15.3% had one comorbidity, 68.6% had two comorbidities and 13.6% had three or more comorbidities). The risk factors of mortality among the studied Page 7605 cases with CRE infections were studied. It was noticed that there was no significant association between age, gender and mortality. Admission to intensive care, CCI=2, and renal dysfunction were significantly associated with death (odds ratio were 12.8, 12.3 and 5.86 respectively) ( Table 2) . When it came to assessment of the risk factors of mortality related to site of infection and pathogen among cases with CRE infections it was noticed that septic shock was a significant risk for death among these cases (odds ratio was 5.29). There was no significant relation between the type of pathogen, the site of infection organism and death (Table 3) . It was found that out of the 23 patients who had started the antibiotic treatment within the first 12 h, 12 patients died and out of the 9 patients who had started antibiotic treatment within 12-24 h, 4 patients died. On the other hand, out of 80 patients who had started the antibiotic treatment after 24 h, 30 patients died. The time of initiation of treatment was not significantly associated with the mortality. Regarding the treatment combination, out of 16 patients who received monotherapy antibiotics, 4 patients died and out of 92 patients who received the combination therapy that included either two, three, or four antibiotics, 42 patients died. Combination therapy that included two drugs was more commonly (n=63) administered than those that included three (n=27) or four (n=2) drugs. Chi-Square test of independence showed that the combined therapy resulted in significantly (p=0.005) more deaths than the monotherapy (Table 4 ). (Table 5 ). Logistic regression model was performed for prediction of death among patients with CRE infections. The significant predictors detected by bivariate analysis were septic shock, ICU admission, renal impairment, CCI=2, and combined therapy. By logistic regression (enter methods) the significant predictors were septic shock, CCI=2, and renal impairment ( Table 6 ). 
Discussion
This study analyzed data of CRE-infected adult patients admitted to the King Abdulaziz University hospital between January 2014 and December 2016 in order to detect the risk factors associated with death among these patients.
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Carbapenem resistance is increasingly reported among the species of Enterobacteriaceae in Saudi Arabia. Increased prevalence of CRE producers and the dissemination of carbapenem-resistance genes are of particular health concern to the health care providers and the Ministry of Health in Saudi Arabia (4) . In our study, the common sources of CRE infection were the chest and the urinary tract. Among the main findings in this study was that admission to intensive care, CCI=2, septic shock and renal dysfunction were significantly associated with death in CRE-infected patients included in this study, while the time of initiation of treatment was not significantly associated with mortality. It was noticed that combined therapy resulted in significantly more deaths than the monotherapy. The significant predictors of death among patients with CRE infections were septic shock, CCI=2, and renal impairment as revealed by the logistic regression. The commonest CRE group isolates, in this study, was Klebsiella pneumoniae (n=106, 89.8%). Similar to our results, Thaden et al. reported K. pneumoniae to be the most prevalent among all CRE isolates (12) . Previous reports have demonstrated that K. pneumoniae-related mortality ranged from 39% to 82% (13, 14) .
Chest and UT were the main sources of CRE infections in this study, and were behind about 30% and 10% of deaths respectively. However, other studies have reported catheter-related bloodstream infections as the prime source of CRE-related mortality (8) . In total, 72 patients survived the hospital course in this study. Furthermore, patients admitted to ICU experienced greater mortality than that of patients in the ward. The high mortality rate observed in this study was consistent with the rates reported in previous studies (15, 16) . The available antibiotic for treating patients with CRE infections is limited because of the resistance to most classes of antibiotics. Previous studies have evaluated the therapeutic regimens used to treat such infections (17) . In the current study, Chi-Square test of independence showed that the combined therapy resulted in significantly more deaths than the monotherapy. CRE has demonstrated resistance to most antimicrobial classes, except agents such as tigecycline and polymyxin (18) . However, the use of these antimicrobials is associated with suboptimal pharmacokinetics and high toxicity (19) . In this study, all patients were sensitive to tigecycline, and 10 out of 26 patients who received the drug died. About 66% of patients for whom the antibiotics were initiated after >24 h (65.2%), died. However, no significant differences in the mortality rates were observed based on the duration of treatment. Previous studies have reported various risk factors associated with CRE infections and patient deaths, such as antibiotic exposure, ICU stay, poor functional status, septic shock, dialysis, age >60 years, ventilation, presence of another multidrug-resistant organism, duration of contact, presence of central venous catheters, and receipt of immunosuppressive drugs (20, 21) . Logistic regression model performed in this study revealed the significant predictors were septic shock, Charlson index two and renal impairment. Other studies have reported different healthcare-associated sources of infection, such as stethoscopes and sinks, hand-washing stations and post-acute care facilities (22) (23) (24) .
Limitations
This study had a few limitations. First, because it was a single-center study, the results may not be applicable to other hospitals with similar infections that may be caused by other factors. Second, we cannot confirm whether the infection was nosocomial or not, as in our hospital, CRE screening is not carried out on new admissions.
Conclusions
In conclusion, this study showed high mortality in infected patients with CRE infections and that the drug monotherapy and combination therapies were not effective in reducing patient mortality. The knowledge of and information on risk factors evaluated in the study could be useful in selecting future treatment regimens to combat such infections and thereby reduce mortality.
